Skip to main content

Immunocore Holdings plc 8-K, filed Nov 6, 2026

Immunocore Holdings plc (IMCR)

8-K 2026-11-06 For: 2026-11-06
View Original
Added on November 06, 2026

About this 8-K

Immunocore Holdings plc filed this 8-K on November 6, 2026.

Immunocore Holdings plc reported KIMMTRAK net revenues of $102.2 million in Q3 2026, while the Phase 3 TEBE-AM trial reached 540 patients; topline overall survival data are expected in the second quarter of 2027. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits